Niraparib in the Treatment of Patients With Advanced PALB2 Mutated Tumors
Status: ACTIVE_NOT_RECRUITING
Study type: INTERVENTIONAL
Conditions: Solid Tumor|Breast Tumor|Colon Tumor, Malignant|Lung Tumor|Urologic Cancer|Pancreatic Cancer|Melanoma|Metastatic Cancer|Locally Advanced Solid Tumor|Esophageal Cancer|Endometrial Cancer|Head and Neck Cancer
Interventions: DRUG: Niraparib
Sponsor: Tempus AI
Collaborators: GlaxoSmithKline